NewAmsterdam Pharma NAMS
$18.41 −$1.10 (-5.64%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $18.32 -0.49%
Open$19.21
Prev close$19.51
Day range$18.29 – $19.78
Volume1.75M
Market cap$2.21B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$19.16M+5,406.9% YoY
Operating profit-$44.19M+19.9% YoY
Net profit-$17.39M+75.9% YoY
Diluted EPS-$0.14+77.0% YoY
Free cash flow-$39.95M-21.8% YoY
Operating cash flow-$39.77M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-900.1%
Net margin-789.9%
Return on equity-30.2%
Return on assets-27.8%
Return on invested capital-32.7%
Current ratio11.76
Liabilities / assets8.3%
Cash & investments$628.24M
Total debt$49,000.00
Net cash (debt)$628.19M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $19.16M | $3.70M | $3.04M | $22.50M | $32,000.00 |
| Total Operating Revenue | $19.16M | $3.70M | $3.04M | $22.50M | $32,000.00 |
| Operating Expense | $63.35M | $68.57M | $61.46M | $248.19M | $66.01M |
| Selling and Admin Expenses | $24.00M | $26.89M | $23.45M | $106.35M | $27.42M |
| Research & Development | $39.36M | $41.67M | $38.01M | $141.83M | $38.59M |
| Operating Profit | -$44.19M | -$64.86M | -$58.42M | -$225.68M | -$65.98M |
| Net Non-Operating Interest Income (Expense) | $5.19M | $5.81M | $5.65M | $27.59M | $6.47M |
| Non-Operating Interest Income | $5.19M | $5.81M | $5.65M | $27.59M | $6.47M |
| Other Income (Expense) | $22.82M | -$5.08M | $4.33M | -$5.73M | -$15.42M |
| Gain on Sale of Security | $22.82M | -$5.08M | $4.33M | -$9.72M | -$15.42M |
| Special Income (Charges) | $0.00 | $0.00 | $0.00 | $3.99M | $0.00 |
| -Less:Restructuring and Mergern & Acquisition | $0.00 | $0.00 | $0.00 | -$3.99M | $0.00 |
| Pretax Profit | -$16.18M | -$64.14M | -$48.44M | -$203.82M | -$74.92M |
| Tax | $1.21M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Profit | -$17.39M | -$64.14M | -$48.44M | -$203.82M | -$74.92M |
| Profit from Continuing Operations | -$17.39M | -$64.14M | -$48.44M | -$203.82M | -$74.92M |
| Net Income to Parent Company | -$17.39M | -$64.14M | -$48.44M | -$203.82M | -$74.92M |
| Net Income to Common Stockholders | -$17.39M | -$64.14M | -$48.44M | -$203.82M | -$74.92M |
| Basic EPS | -$0.14 | -$0.52 | -$0.40 | -$1.72 | -$0.63 |
| Diluted EPS | -$0.14 | -$0.52 | -$0.40 | -$1.72 | -$0.63 |
| -General & Admin Expense | – | – | – | $106.35M | $27.42M |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $687.99M | $704.45M | $732.64M | $769.28M | $769.28M |
| Total Current Assets | $672.16M | $659.21M | $658.04M | $675.70M | $675.70M |
| Cash and Cash Equivalents & Short-Term Investments | $628.24M | $633.85M | $636.11M | $636.24M | $636.24M |
| -Cash and Cash Equivalents | $423.13M | $424.15M | $457.61M | $490.00M | $490.00M |
| -Short Term Investments | $205.11M | $209.70M | $178.50M | $146.24M | $146.24M |
| Receivables | $27.00M | $5.35M | $8.22M | $23.15M | $23.15M |
| -Taxes Receivable | $303,000.00 | $235,000.00 | $206,000.00 | $231,000.00 | $231,000.00 |
| -Other Receivables | $26.69M | $5.11M | $8.02M | $22.92M | $22.92M |
| Prepaid Assets | $15.43M | $18.65M | $12.38M | $14.99M | $14.99M |
| Restricted Cash | $1.50M | $1.36M | $1.34M | $1.32M | $1.32M |
| Total Non-Current Assets | $15.82M | $45.25M | $74.60M | $93.58M | $93.58M |
| Net PPE | $629,000.00 | $493,000.00 | $400,000.00 | $568,000.00 | $568,000.00 |
| -Gross PPE | $629,000.00 | $493,000.00 | $400,000.00 | $568,000.00 | $568,000.00 |
| Investments and Advances | $14.88M | $44.41M | $71.24M | $92.61M | $92.61M |
| -Available for Sale Securities | $14.88M | $44.41M | $71.24M | $92.61M | $92.61M |
| Goodwill and Other Intangible Assets | $312,000.00 | $343,000.00 | $375,000.00 | $407,000.00 | $407,000.00 |
| Total Liabilities | $57.20M | $73.03M | $67.42M | $85.85M | $85.85M |
| Total Current Liabilities | $57.15M | $72.97M | $67.42M | $85.79M | $85.79M |
| Payables | $4.63M | $5.42M | $8.09M | $8.97M | $8.97M |
| -Accounts Payable | $4.63M | $5.42M | $8.09M | $8.97M | $8.97M |
| Current Accrued Expenses | $7.94M | $4.71M | $2.82M | $6.07M | $6.07M |
| Short-Term Debt and Capital Lease Obligation | $27,000.00 | $26,000.00 | $23,000.00 | $136,000.00 | $136,000.00 |
| -Current Capital Lease Obligation | $27,000.00 | $26,000.00 | $23,000.00 | $136,000.00 | $136,000.00 |
| Current Deferred Liabilities | $5.71M | $2.80M | $3.99M | $3.99M | $3.99M |
| Other Current Liabilities | $31.33M | $54.45M | $50.23M | $57.27M | $57.27M |
| Total Non-Current Liabilities | $49,000.00 | $56,000.00 | $0.00 | $66,000.00 | $66,000.00 |
| Long Term Debt and Capital Lease Obligation | $49,000.00 | $56,000.00 | $0.00 | $66,000.00 | $66,000.00 |
| -Long Term Capital Lease Obligation | $49,000.00 | $56,000.00 | $0.00 | $66,000.00 | $66,000.00 |
| Total Equity | $630.78M | $631.42M | $665.22M | $683.43M | $683.43M |
| Stockholders' Equity | $630.78M | $631.42M | $665.22M | $683.43M | $683.43M |
| Capital Stock | $15.03M | $14.74M | $14.59M | $14.28M | $14.28M |
| -Common Stock | $15.03M | $14.74M | $14.59M | $14.28M | $14.28M |
| Additional Paid-In Capital | $1.50B | $1.49B | $1.46B | $1.43B | $1.43B |
| Retained Earnings | -$892.36M | -$874.97M | -$810.83M | -$762.39M | -$762.39M |
| Gains/Losses Not Affecting Retained Earnings | $3.62M | $3.86M | $4.22M | $4.79M | $4.79M |
| Non-Current Prepaid Assets | – | – | $2.59M | – | – |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$39.77M | -$39.21M | -$30.60M | -$147.78M | -$40.88M |
| Net cash flow from continuing operations | -$39.77M | -$39.21M | -$30.60M | -$147.78M | -$40.88M |
| Net Income from Continuing Operations | -$17.39M | -$64.14M | -$48.44M | -$203.82M | -$74.92M |
| Gain/Loss from Continuing Operations | -$22.82M | $5.09M | -$4.32M | $5.74M | $15.43M |
| Depreciation & Depletion & Amortization | $67,000.00 | $59,000.00 | $62,000.00 | $220,000.00 | $59,000.00 |
| Other Non-Cash Items | $2,000.00 | $3,000.00 | -$16,000.00 | – | – |
| Change in Working Capital | -$12.15M | $1.44M | $4.10M | -$7.94M | $4.57M |
| -Change in Prepaid Assets | -$19.41M | $135,000.00 | $15.22M | -$13.28M | -$10.06M |
| -Change in Payables and Accrued Expense | $4.35M | $2.50M | -$11.12M | $7.36M | $10.64M |
| -Change In Other Working Capital | $2.91M | – | – | -$2.02M | $3.99M |
| Net cash flow from investing | $33.70M | -$4.76M | -$11.51M | -$174.92M | -$21.14M |
| Net Cash Flow from Continuing Investing Activities | $33.70M | -$4.76M | -$11.51M | -$174.92M | -$21.14M |
| Net PPE Purchase and Sale | -$177,000.00 | -$80,000.00 | -$38,000.00 | -$246,000.00 | -$100,000.00 |
| Net Investment Purchase and Sale | $33.88M | -$4.68M | -$11.47M | -$174.67M | -$21.04M |
| Financing Cash Flow | $5.45M | $11.04M | $11.07M | $29.52M | $13.68M |
| Net Cash Flow from Continuing Financing Activities | $5.45M | $11.04M | $11.07M | $29.52M | $13.68M |
| Proceeds from Stock Option Exercised | $5.45M | $11.04M | $11.07M | $31.11M | $13.68M |
| Ending Cash Balance | $424.63M | $425.51M | $458.94M | $491.32M | $491.32M |
| Net Change in Cash | -$623,000.00 | -$32.94M | -$31.05M | -$293.18M | -$48.33M |
| Beginning Cash Balance | $425.51M | $458.94M | $491.32M | $771.74M | $539.72M |
| Effect of Exchange Rate Changes | -$260,000.00 | -$500,000.00 | -$1.33M | $12.76M | -$60,000.00 |
| Free Cash Flow | -$39.95M | -$39.29M | -$30.64M | -$148.03M | -$40.98M |
| Net Common Stock Issuance | – | – | – | $0.00 | $0.00 |
| Net Other Financing Charges | – | – | – | -$1.59M | $0.00 |
No comments yet — be the first to weigh in on NAMS.
Sign in to join the discussion.